Resources Repository
-
ArticlePublication 2022Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face …
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face of uncertainty. This study aimed to quantify consequences of approving therapies or pursuing further research. The authors used a cohort state-transition model for hospitalized patients with COVID-19 to estimate quality-adjusted life-years (QALYs) and costs associated with multiple drug regimens and usual care. For each they assessed immediate approval, use only in research, emergency use authorization or reject. They conducted cost-effectiveness…
State-Transition | Value of Information | Europe | North America | Benefit-Cost Analysis | Infectious Diseases | Policy/Regulation | Economics/Finance -
OrganizationWeb Portal 2024Society for Medical Decision Making
The Society for Medical Decision Making (SMDM), founded in 1979, works to improve health and …
The Society for Medical Decision Making (SMDM), founded in 1979, works to improve health and clinical care of individuals and populations through the advancement of systematic methods to address decision-making under conditions of uncertainty, and to provide a training ground for scholars in the field of medical decision making. Members include researchers, clinicians, educators, managers and policy makers from varied backgrounds and academic disciplines. SMDM provides opportunities for collaboration, networking and mentorship to professionals and trainees…
Priority Setting/Ethics | Value of Information | Europe | North America | Preferences/Values | Costing Methods | Decision Analysis | Cost-Effectiveness Analysis | Health/Medicine | Global -
OrganizationWeb Portal 2024Institute for Clinical and Economic Review (ICER)
ICER is a non-profit organization that evaluates evidence on a range of topics including the value …
ICER is a non-profit organization that evaluates evidence on a range of topics including the value of medical tests, treatments and delivery system innovations and moves that evidence into action to improve the health care system. To accomplish this goal ICER performs analyses on effectiveness and costs, supports specific programs, and develops reports using innovative methods that make it easier to translate evidence into decisions that can align efforts to use evidence to drive improvements in both…
Priority Setting/Ethics | Value of Information | Europe | North America | Preferences/Values | Evidence Synthesis | Cost-Effectiveness Analysis | Technology Assessment | Infectious Diseases | Chronic Disease/Risk | Mental Health | Health Systems | Business/Industry | Economics/Finance | Government/Law | Health/Medicine | Science/Technology -
ArticlePublication 2023Top and Bottom Longevity of Nations
Similar to the study of the distribution of income within countries, population-level health disparities can …
Similar to the study of the distribution of income within countries, population-level health disparities can be examined by analyzing the distribution of age at death. This article exposes a characterization of the age-at-death distribution across populations with a focus on the lower and upper tails of the distribution. These metrics, specifically the gap measures in age and share across the 10th and 90th percentiles of the distribution, enable a systematic comparison of national performances, which…
Priority Setting/Ethics | Europe | North America -
ArticlePublication 2021Measuring the Impact of COVID-19 Vaccine Misinformation on Vaccination Intent in the U.K. and U.S.
Widespread acceptance of a vaccine for SARS-CoV-2 will be the next major step to fight …
Widespread acceptance of a vaccine for SARS-CoV-2 will be the next major step to fight the COVID-19 pandemic, but high uptake achievement will be a challenge and may be impeded by online misinformation. This article is a randomized controlled trial in the U.K. and the U.S. with the objective to quantify how exposure to online misinformation around COVID-19 vaccines affects intent to vaccinate to protect oneself or others. The authors report that in both countries…
Decision Psychology | Europe | North America | Preferences/Values | Infectious Diseases | Child/Nutrition | Social Determinants | Culture/Society | Health/Medicine | Science/Technology -
ArticlePublication 2016Country-Level Cost-Effectiveness Thresholds
This article estimates the cost-effectiveness thresholds (CETs) for health interventions in several low and middle-income …
This article estimates the cost-effectiveness thresholds (CETs) for health interventions in several low and middle-income countries (LMICs), based on opportunity costs. When there are constraints on a health care system’s budget or ability to increase expenditures, additional costs imposed by interventions have an “opportunity cost” in terms of the health foregone because other interventions cannot be provided. The authors argue that cost-effectiveness thresholds should reflect health opportunity cost and aim to calculate these in four…
Priority Setting/Ethics | Europe | Latin America & Caribbean | Cost-Effectiveness Analysis | Health Systems | Economics/Finance | Health/Medicine | Sub-Saharan Africa | Middle East & North Africa | Asia & Pacific -
ReviewPublication 2015Population Health: Behavioral and Social Science Insights
This book comprises 23 chapters focused on what the effects of various behavioral and social factors …
This book comprises 23 chapters focused on what the effects of various behavioral and social factors on longevity, disability and illness, and quality of life, primarily at the population level. Factors such as access to health care, educational attainment, nutrition, physical activity, use of tobacco products, and non-communicable diseases are considered, along with many other determinants of health and longevity. Of particular interest for health decision scientists are the following chapters: In Section 4: The Science…
Priority Setting/Ethics | Europe | North America | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Health/Medicine | Global -
ArticlePublication 2011Model-Based Analyses to Compare Health and Economic Outcomes of Cancer Control: Inclusion of Disparities
In order to identify strategies that improve both population health and ensure its equitable distribution, …
In order to identify strategies that improve both population health and ensure its equitable distribution, the authors developed a typology of cancer disparities that considers types of inequalities among black, white, and Hispanic populations across different cancers. This paper reports on the typology using an existing disease simulation model of cervical cancer that was calibrated to clinical, epidemiological, and cost data in the United States and presents characteristics important for policy discussions. The typology proposed…
Priority Setting/Ethics | State-Transition | North America | Cost-Effectiveness Analysis | Chronic Disease/Risk | Social Determinants | Health Systems | Clinical Care | Culture/Society | Health/Medicine | Science/Technology -
ArticlePublication 2023Cost-Effectiveness of Pharmacist Prescribing for Managing Hypertension
This study estimates the cost-effectiveness of implementing a pharmacist-prescribing intervention to improve blood pressure control …
This study estimates the cost-effectiveness of implementing a pharmacist-prescribing intervention to improve blood pressure control in the US. A cost-effectiveness analysis was conducted using a Markov model based on the pharmacist-prescribing intervention used in The Alberta Clinical Trial in Optimizing Hypertension (or RxACTION). Outcomes included cardiovascular (CV) events, end-stage kidney disease events, life years, quality-adjusted life years (QALYs), lifetime costs, and lifetime incremental cost-effectiveness ratio (ICER). Costs were based on reimbursement rates, published literature, national…
State-Transition | North America | Mathematical Models | Cost-Effectiveness Analysis | Chronic Disease/Risk | Clinical Care | Health/Medicine